Unfortunately, anti–PD-1 as monotherapy does not provide the same survival benefits in patients with acral and mucosal melanoma as it does in patients with cutaneous melanomas (Tang et al., 2020). The gene discussed is RPL17; the disease is cutaneous melanoma.